PT  - JOURNAL ARTICLE
AU  - Bisanzio, Donal
AU  - Roberts, Sarah T.
AU  - Stelmach, Rachel D.
AU  - McClellan, Kendall N.
AU  - Bobashev, Georgiy
AU  - Adams, Joella
AU  - Karriker-Jaffe, Katherine
AU  - Endres-Dighe, Stacy M.
AU  - Saalim, Khalida
AU  - Blackburn, Natalie
AU  - Nyblade, Laura
TI  - A novel modelling framework to simulate the effects of HIV stigma on HIV transmission dynamics
AID  - 10.1101/2024.10.01.24314728
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.01.24314728
4099  - http://medrxiv.org/content/early/2024/10/02/2024.10.01.24314728.short
4100  - http://medrxiv.org/content/early/2024/10/02/2024.10.01.24314728.full
AB  - Introduction HIV remains a global public health challenge, with social determinants such as stigma influencing transmission dynamics, access to testing, and treatment. HIV stigma shapes both individual behaviour and community responses to HIV. However, modelling approaches have rarely represented the complex role of stigma in HIV epidemics. Our study introduces an innovative modelling framework designed to capture the interplay between stigma and HIV transmission dynamics.Methods We modelled effects of anticipated, internalised, and experienced HIV stigma on HIV testing, antiretroviral treatment initiation, and treatment adherence. We built an individual-based model representing the HIV epidemic (HIV-IBM) in a USA-like population of 3 million individuals that accounts for community demography, behaviour, and healthcare access. Stigma parameters were based on a scoping review focused on the prevalence and effects of stigma in people living with and without HIV. HIV-IBM was used to assess effects of interventions targeting different types of stigma. We tested reductions of stigma by 50% and 100% across the simulated population and performed a sensitivity analysis to identify effects of each type of stigma on the simulated HIV epidemic.Results Without reduced stigma, the HIV-IBM had an annual incidence rate of 12.6 (95% credible interval [CI]: 11.4-13.5) new cases per 100,000 people. Reducing the overall level of stigma in the population by 50% resulted in an annual incidence rate of 9.6 (95% CI: 8.6-10.3) per 100,000, and a 100% reduction in stigma resulted in an annual incidence rate of just 6.8 (95% CI: 6.1-7.3) per 100,000. In addition to reducing HIV incidence, reducing stigma resulted in a substantial increase of viral suppression among people living with HIV (50% stigma reduction: +10.5%; 100% stigma reduction: +16.4%). Sensitivity analysis showed that outcomes resulting from interventions targeting each type of stigma were highly heterogeneous.Conclusion Simulation results suggest that reducing HIV stigma could have a large effect on HIV incidence and viral suppression. Our model framework provides a dynamic approach to understanding the role of stigma in HIV outcomes that facilitates exploration of stigma reduction strategies and offers insights to inform evidence-based policies and interventions for reducing stigma and curtailing HIV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the RTI Fellows BUILD program at RTI InternationalAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesARTAntiretroviral therapyCICredible intervalHIVHuman immunodeficiency virusHIV-IBMIndividual-based model representing the HIV epidemicMSMMen who have sex with menMSMSWMen who have sex with both men and womenMSWMen who have sex with womenWSMWomen who have sex with menWSWWomen who have sex with womenWSWSMWomen who have sex with both women and menPrEPPre-exposure prophylaxisPLWHPeople living with HIVPWIDPeople who inject drugs